Live Analyst Rating Changes 35650 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Rudy Li
WLF

Rudy Li

Wall Street Analyst
★★★★★
#172
on 13Foresight · ranked by our own returns
64%
Success Rate
+21.4%
Average Return
14 of 22 calls profitable · +74.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 64% of Rudy Li's ratings turned a profit when each position was held for 2 year — averaging +21.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 4 Hold 0 Sell
Rudy's Stock Coverage 20 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
HRMY
Harmony Biosciences Holdings
Aug 26, 2026 BUY Strong Buy
+25.2% avg upside
14 analysts
$60.00
52.77% Upside
+4.0% ·
IMUX
Immunic
Aug 11, 2026 BUY Strong Buy
+319.4% avg upside
22 analysts
$25.00
180.68% Upside
-39.6% ·
STOK
Stoke Therapeutics
Aug 03, 2026 BUY Strong Buy
+59.2% avg upside
18 analysts
$40.00
54.51% Upside
-16.1% ·
QURE
uniQure
Jul 29, 2026 BUY Strong Buy
+132.5% avg upside
30 analysts
$65.00
165.27% Upside
+6.7% ·
CMPS
COMPASS Pathways
Jul 07, 2026 BUY Strong Buy
+70.9% avg upside
20 analysts
$18.00
38.79% Upside
+1.8% ·
SPTX
Seaport Therapeutics, Inc.
Jul 07, 2026 HOLD Strong Buy
+103.2% avg upside
8 analysts
— +18.1% ·
LBRX
LB Pharmaceuticals, Inc.
Jul 07, 2026 BUY Strong Buy
+40.9% avg upside
8 analysts
$45.00
20.62% Upside
+8.9% ·
ACAD
ACADIA Pharmaceuticals
May 06, 2026 BUY Strong Buy
+77.4% avg upside
43 analysts
$33.00
63.18% Upside
-5.5% ·
NBIX
Neurocrine
Apr 06, 2026 BUY Strong Buy
+35.0% avg upside
37 analysts
$160.00
15.73% Upside
+6.0% ·
PRAX
Praxis Precision Medicines
Apr 06, 2026 BUY Strong Buy
+98.4% avg upside
24 analysts
$500.00
77.92% Upside
-7.9% ·
DNLI
Denali Therapeutics
Feb 23, 2026 HOLD Strong Buy
+86.8% avg upside
24 analysts
— +0.6% ·
DFTX
Definium Therapeutics
Feb 23, 2026 BUY Strong Buy
+38.8% avg upside
23 analysts
$25.00
34.51% Downside
+126.6% ·
AXSM
Axsome Therapeutics
Feb 23, 2026 BUY Strong Buy
+26.1% avg upside
30 analysts
$230.00
23.60% Upside
+6.0% ·
XENE
Xenon
Feb 23, 2026 BUY Strong Buy
+52.6% avg upside
28 analysts
$60.00
61.13% Upside
-14.0% ·
ALKS
Alkermes
Feb 23, 2026 BUY Strong Buy
+7.7% avg upside
34 analysts
$45.00
10.36% Upside
+26.9% ·
GB:0NZT
UCB SA
Feb 23, 2026 BUY Strong Buy
+5.8% avg upside
19 analysts
$340.00
64.41% Upside
· ·
PRTA
Prothena
Dec 31, 2025 BUY Buy
+185.2% avg upside
14 analysts
$18.00
104.94% Upside
-8.1% ·
ANRO
Alto Neuroscience, Inc.
Oct 20, 2025 BUY Strong Buy
+20.8% avg upside
13 analysts
$15.00
43.63% Downside
+143.6% ·
RVPH
Reviva Pharmaceuticals Holdings
Sep 29, 2025 BUY Strong Buy
+9055.5% avg upside
9 analysts
$40.00
8285.74% Upside
-92.2% ·
DRUG
Bright Minds Biosciences
May 21, 2025 BUY Strong Buy
+171.1% avg upside
11 analysts
$80.00
60.93% Upside
+70.2% ·
🔒 15 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Rudy Li — Frequently Asked Questions
How accurate are Rudy Li's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Rudy's ratings were profitable over a one-year hold, with an average return of +32.1% per rating, or +77.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Rudy ranked on 13Foresight?
Rudy Li is currently ranked #172 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Rudy cover?
Rudy most recently has ratings on HRMY, IMUX, STOK, QURE, CMPS, SPTX, LBRX, ACAD, NBIX, PRAX, DNLI, DFTX and 8 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.